Form 4: ALUMIS CEO Babler Granted 745,875 Stock Options

ALUMIS INC. President, CEO, and Chairman Martin Babler was granted 745,875 stock options with an exercise price of $26.31, vesting over four years.

Summary

• Martin Babler, President, CEO, and Chairman of ALUMIS INC., was granted 745,875 stock options.
• The options have an exercise price of $26.31 per share.
• The grant date for these options was January 26, 2026.
• Vesting schedule: 25% of the shares vest on January 26, 2027, with the remaining shares vesting in equal monthly installments over the subsequent 36 months.
• The options expire on January 25, 2036.
• Vesting is contingent upon Mr. Babler's continuous service to the Issuer, as defined in the Issuer's 2024 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of a significant stock option package to the CEO is generally a positive signal, indicating management's long-term commitment and alignment with shareholder interests. It incentivizes the CEO to drive stock price appreciation. The long vesting period and expiration date reinforce this long-term view. However, it's not a direct operational or financial performance indicator, hence not extremely high.

Positives

• The grant of a significant number of stock options (745,875) to the CEO aligns management's interests with long-term shareholder value creation.
• The options have a long expiration date (January 25, 2036), providing ample time for the stock price to appreciate and for the options to become in-the-money.

Negatives

• The exercise price of $26.31 indicates the stock needs to trade above this level for the options to be in-the-money and provide value to the CEO.
• The vesting schedule extends over four years, meaning the full benefit is not immediate and is tied to continued employment, which could be perceived as a long-term commitment rather than an immediate reward.

Risks

• The value of the stock options is entirely dependent on the future market price of ALUMIS INC. common stock exceeding the exercise price of $26.31.
• Vesting is subject to the Reporting Person's Continuous Service, meaning unvested options could be forfeited if employment ceases prior to full vesting.

Future Outlook

The stock option grant, with its long-term vesting schedule and expiration date, suggests an expectation of sustained growth and value creation for ALUMIS INC. over the next decade, aligning executive incentives with long-term company performance.

Industry Context

Executive stock option grants are a common practice in the biotechnology and pharmaceutical industries, particularly for growth-oriented companies like ALUMIS INC., to attract, retain, and incentivize key leadership. This grant aligns with typical industry practices for executive compensation, tying a significant portion of the CEO's potential compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of 745,875 stock options to a CEO of a company like ALUMIS INC. is a substantial equity award, comparable in scale to grants seen in similar-stage biotech or specialty pharma companies aiming to incentivize long-term value creation.
• The 4-year vesting schedule (1-year cliff then monthly) is a standard industry practice designed to ensure executive retention and align interests with long-term shareholder returns, similar to compensation structures at companies such as Moderna or BioNTech during their growth phases.
• An exercise price of $26.31, likely the market price on the grant date, is standard for incentive stock options, ensuring that the executive benefits only if the company's stock price appreciates from the grant date.

Stakeholder Impact

• Shareholders: Potential positive impact as CEO's incentives are aligned with increasing shareholder value through stock price appreciation.
• Employees: May signal stability in leadership and a long-term vision for the company.

Next Steps

• Monitor the company's stock performance relative to the option exercise price of $26.31.
• Observe future SEC filings for any changes in Martin Babler's beneficial ownership or additional equity grants.

Key Dates

Recommendation

This Form 4 filing reports a standard executive compensation event—a stock option grant to the CEO. While it aligns management's interests with long-term shareholder value and signals confidence, it does not provide new operational or financial data to warrant a change in investment thesis. The grant itself is a neutral to slightly positive event, reinforcing a 'hold' position for investors already in ALMS, pending further fundamental analysis of the company's performance and prospects.

Keywords

ALUMIS INC., ALMS, Martin Babler, Stock Options, CEO Compensation, Executive Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Vesting Schedule